🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Capricor Therapeutics, Inc. CAPR R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.capricor.com
Company Profile ↓
$9.40
+13.25% 1Y
Mkt Cap$544.37M
P/E-4.05
P/B0.85
52W High$35.34
52W Low$3.85
Book Value$4.83
EPS (TTM)$-2.32

Company Overview

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.05.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:+13.25%
6 Months:-66.31%
3 Months:-64.81%
1 Month:+124.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 18% of range
$3.85 $35.34
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)49.89 · Neutral
Price Performance
1M+124.88%
3M-64.81%
6M-66.31%
1Y+13.25%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 73.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.05
Industry PE
25.17
Forward P/E
-7.43
PEG Ratio
0.38
Book Value
$4.83
Price to Book
0.85
P/S
-
EV/EBITDA
0.23
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-33.78%
ROE
-56.40%
ROA
-31.23%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.59
EPS (TTM)
$-2.32

Balance Sheet & Liquidity

Debt/Equity
0.05
Quick Ratio
8.28
Current Ratio
8.42
Debt
$14.78M
Total Assets
$326.28M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
9.44%
Chg in Prom Hold
-0.01%
FII / Inst Holding
76.07%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$544.37M
Total Revenue (TTM)
$0
EBITDA
$-117.91M
Free Cash Flow
$-70.47M
Operating Cash Flow
$-92.63M
Shares Outstanding
57.91M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CAPR Capricor Therapeutics, Inc. R2KR3KPHARMA 9.40 -4.05 $544.37M 0.00% -33.78% -56.40% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 233.29K189.51K80.43K1.04M1.04M1.30M1.79M1.29M1.31M1.22M1.13M746.78K880.81K996.46K313.27K400.07K403.96K219.25K230.50K410.35K142.07K185.69K49.86K16.86K40.82K204.08K---1.59M2.99M3.92M6.19M4.91M3.97M2.26M----
Operating Income -1.43M-1.62M-1.49M-1.19M-1.48M-1.49M-3.41M-3.06M-2.85M-4.21M-4.61M-5.24M-3.57M-3.38M-2.64M-3.69M-4.16M-4.17M-2.56M-2.07M-1.63M-2.11M-3.49M-3.91M-5.16M-5.08M-4.31M-7.83M-7.32M-6.48M-8.18M-7.75M-6.86M-10.27M-11.59M-13.01M-24.98M-27.72M-26.28M-36.77M
Net Income -1.42M-1.62M-1.55M-1.21M-1.53M-1.54M-3.48M-3.12M-2.91M-4.27M-4.69M-5.33M-3.67M-3.47M-2.73M-3.67M-4.12M-4.14M-2.52M-2.05M-1.61M-2.08M-3.48M-3.91M-5.15M-4.75M-3.93M-7.82M-7.11M-6.37M-7.77M-7.37M-6.39M-9.79M-11.00M-12.56M-24.39M-25.91M-24.57M-33.94M
Diluted EPS -----------------------0.23-0.23-0.23-0.21-0.17-0.32-0.29-0.26-0.31-0.29-0.25-0.31-0.35-0.38-0.53-0.57-0.54-0.59
R&D Expense 1.19M1.31M1.01M1.37M1.86M1.97M3.81M3.43M3.19M4.34M4.31M4.73M3.26M3.13M1.86M2.70M3.39M3.13M1.81M1.64M857.76K1.16M1.93M2.63M3.30M3.50M2.51M5.12M4.97M5.50M7.66M8.82M10.03M11.10M12.50M11.81M18.92M22.05M20.36M27.38M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -----1.35M195.50K503.23K4.79M5.52M4.00M2.67M1.67M1.01M310.25K244.90K2.55M25.18M22.27M0
Operating Income -----6.29M-4.90M-2.10M-6.90M-6.02M-12.61M-16.98M-12.86M-15.33M-7.73M-13.69M-20.94M-29.70M-24.08M-42.56M-108.14M
Net Income -1.17M-979.08K-630.86K-148.97K-1.06M-1.15M-2.07M-8.89M-6.22M-12.86M-18.81M2.43M-15.19M-7.64M-13.66M-20.02M-29.02M-22.29M-40.47M-105.04M
Diluted EPS -----------1.010.09-0.52--0.88-0.87-1.18-0.83-1.15-2.26
R&D Expense ----4.08M4.14M2.63M5.20M7.79M13.76M16.04M10.77M12.07M5.14M8.46M13.57M21.82M36.45M49.97M84.45M

Balance Sheet (Annual)

Figures in USD.

Metric Jul 2005Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ------3.67M1.37M5.42M5.54M13.63M16.07M18.75M16.27M9.25M11.11M34.62M41.33M50.09M58.73M170.48M355.95M
Total Equity 001.84M863.17K252.55K911.77K1.79M1.66M4.89M-534.88K-6.25M-1.03M-4.00M11.23M4.62M6.84M28.20M31.37M11.79M22.60M145.46M305.79M
Cash & Equivalents 0----3.18M3.38M1.55M170.11K1.73M8.03M5.57M3.20M6.14M4.26M3.90M32.67M34.89M9.60M14.69M11.29M287.85M
Total Liabilities -------541.45K529.17K6.07M19.88M17.10M22.75M5.05M4.63M4.27M6.42M9.96M38.31M36.13M25.02M50.16M
Current Liabilities ------1.07M541.45K529.17K2.05M6.30M6.53M4.90M1.67M1.26M897.99K2.97M4.13M23.59M31.27M21.03M35.84M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.32M-4.65M-2.19M----14.45M-14.23M-13.86M-6.82M-10.05M-16.81M4.92M-25.60M-40.00M-69.81M
Investing Cash Flow -2.21K-1.99K0----5.19M4.98M4.67M-3.00M5.44M-1.20M-35.07M5.11M-116.18M97.48M
Financing Cash Flow 4.52M2.31M1.19M---18.63M11.58M6.85M9.18M33.38M20.23M4.87M25.58M152.77M248.89M
Capital Expenditure -2.21K-1.99K-13.43K-56.12K-162.69K-129.70K-191.97K-32.19K-316.49K-0-547.60K-1.20M-2.00M-1.31M-1.17M-2.90M
Free Cash Flow -4.32M-4.65M-2.20M----14.65M-14.26M-14.18M-6.82M-10.60M-18.01M2.92M-26.91M-41.16M-72.72M
Share Buybacks --------01930-----

Ratios (Annual)

Figures in %.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------------
Operating Margin % ------361.7%-1,074.2%-1,371.7%-125.7%-228.6%-424.6%-482.4%-917.0%-769.5%-4,412.6%-8,549.9%-1,163.9%-95.6%-191.1%-
Net Margin % ------84.9%-1,059.5%-1,767.0%-129.9%-233.0%-470.3%91.2%-908.9%-760.4%-4,401.9%-8,175.9%-1,137.4%-88.5%-181.7%-
ROE % -63.8%-113.4%-249.8%-16.3%-59.0%-69.4%-42.3%1,662.4%99.5%1,246.1%469.8%21.7%-329.1%-111.7%-48.4%-63.8%-246.2%-98.6%-27.8%-34.4%
ROCE % -----242.4%-589.7%-42.9%-198.1%-82.1%-132.2%-122.6%-88.1%-191.8%-75.7%-43.3%-56.3%-112.0%-87.7%-28.5%-33.8%

Shareholding Pattern

Insiders
9.44%
Institutions
76.07%
Public Float
84.00%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 7.13% 4.15M $39.75M
2 Tang Capital Management, LLC 7.05% 4.10M $39.32M
3 Montanova Capital LLC 7.04% 4.09M $39.25M
4 State Street Corporation 5.84% 3.40M $32.58M
5 Vanguard Capital Management LLC 3.95% 2.30M $22.03M
6 Goldman Sachs Group Inc 2.71% 1.58M $15.13M
7 RA Capital Management, L.P. 2.59% 1.51M $14.46M
8 Boxer Capital Management, LLC 2.40% 1.40M $13.38M
9 Geode Capital Management, LLC 2.36% 1.37M $13.16M
10 FMR, LLC 1.96% 1.14M $10.91M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CAPR

Google News Mon, 07 Sep 2026

GOOGL Stock Price Today - Alphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE5GV3FIb3o4T1ZMbUZxeGdxTXBNenlYM1FQWWt5X1EySTNJYU9keEN1Y3lFTVYzQTVQUDJTRmR2OUtvOENRbkM0M2dQYw?oc=5" target="_blank">GOOGL Stock Price Today - Alphabet Inc Class A News, Charts, Reta…

Google News Mon, 07 Sep 2026

CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - TradingView

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQd2RlclpBMFhIem5uMWZqVlp4NW5jRGhFN290ZXl0Ykx0UHc0R3NxelFuYXNucDBjNzFDbjRTY0c0S0NfWGhEVkhVa0ZZM0w4S1JuNjZVQ3ZLQXdycF9DYUtFcTdWNUxwMUlxazQtbE1yTjJqQUtwQnJIWmtTYm5YNE1ZLXVzMmRoNzZObG…

Google News Fri, 21 Aug 2026

CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOLU9NUWtvWFF0TUMxME9paU5yLTlCV2pPaS1sTVVyNXIzR0xQajNOMmlBMF9HTFMzSmxpc1ZiYTZ0NUlESWl0MDVzTW9LRjdFSUE5eTJHMDBhZWxJTlBkTTQtTjU0cVdmSk1GVHFUWERsbzgxak5nd1c0eEtqVFdjb0RNdUVmVlhqdGJyaT…

Google News hu, 03 Sep 2026

CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman - PR Newswire

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxPVjk4cklxZDJnY0x2NnF4T0pEejVUVHVXQjV5dVdadmhVbDgxdlpLWm5MUnNKTEs4czNBRFJQdXpjVzRaaFl2R19LWHR1d3hjOVpDYnZDN0VPNk5LdUU0X0hQTmVCZHFVdkFheFlvckRRSC1mYi1MdWpRbEtyc3BZVW82QmQ3YVV1T2xXd1…

Google News Wed, 02 Sep 2026

CAPR Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against Capricor Therapeutics, Inc. - TMX Newsfile

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxQTkhUMVZybTRMNW9wZlFBeHlmLUp1VUhWT3ZpSzRfbHp6d3h6eHc3QnBfRnQ1UkI1X2hOY0FKNUktZ2xRN2ZhNmUzRlh0VUpqRFpBakx4N3A2eHY1RWJOb2x6bU5sUzJWN1VfcWw0TndFeHpoOFdncGVFaXFiSC1aOTdwNVNEeXlvWVNvWE…

Google News hu, 03 Sep 2026

$CAPR stock is down 8% today. Here's what we see in our data. - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQb05ZZDl4RWdXajhTclVUV2g4WW0taUxkN1gyNEI5UXhFZzAyWjdNbExFTlM1bDRQSjZNVXo4dzhTODk0OGhTX3RWRHB2Q1VHdEhKZzdLRFFsN0hWd3NSYjRqbXF3OXFTcXN2M3Jtd05kZXpqbmJacnN4Z0tVYTNCMzR6TUxkRTExUmZCYW…

CAPR — Frequently Asked Questions

What is the current share price of Capricor Therapeutics, Inc. (CAPR)?

As of 2026-09-07 16:24 PDT, Capricor Therapeutics, Inc. (CAPR) trades at $9.40 on NasdaqGS. Its 52-week range is $3.85 to $35.34.

What is the market capitalisation of CAPR?

Capricor Therapeutics, Inc. (CAPR) has a market capitalisation of $544.37M on NasdaqGS.

What is the P/E ratio of CAPR?

CAPR trades at a trailing price-to-earnings (P/E) ratio of -4.05. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.85.

What is the return on equity (ROE) of CAPR?

CAPR has a return on equity (ROE) of -56.40%. Its return on capital employed (ROCE) is -33.78%.

Is CAPR a good stock to buy?

This page provides a data-driven analysis of Capricor Therapeutics, Inc. (CAPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space